Abstract 2839
Background
Obesity carries a high risk of breast cancer with worse treatment outcome. Different molecular subtype and prognostic factors are linked to high body mass index (BMI) and affects overall and progression-free survival.
Methods
All 950 breast cancer patients presented to kasr Alainy oncology center (NEMROCK) from 2004 - 2014 at Al kasr alainy oncology center (NEMROCK) were followed up with a median period of 4.2years till Dec 2018. The body mass index (BMI) was assessed at diagnosis in 760 female patients. Disease-free survival (DFS) and overall survival (OS) were assessed and compared between three groups: non-obese (BMI <30), obese (BMI 30-34.9) and severely obese (BMI >40).
Results
The mean age was 50.1 years with Obesity in 63.29% of cases (23.82% and 39.47% in obese and severely obese respectively). Significant correlations between non-obese and severely obese with age (52 vs.48 years, p < 0.001), menopausal status (31.3 vs.46.9%, p < 0.001), molecular types (non- luminal; 25 vs. 50% p < 0.011), Her2 status (44.4 vs. 27.2%, p = 0.014) and hormonal therapy (Tamoxifen alone, 44.3 vs. 30.4%, p = 0.001). Mean Overall survival(OS) was significantly better in non-obese groups compared to obese and severely obese (102.5, 80, 88months, P=value 0.019), with no impact on DFS (p = 0.40).In multivariate analysis, lymph node stage (p < 0.001; OR: 1; 95% CI: 0.07-0.46), BMI (p = 0.001; OR: 1; 95% CI: 0.14-0.61), and hormonal treatment tamoxifen alone(p = 0.001; OR: 1; 95%CI: 1.4-16.4) remained significantly associated with OS.
Conclusions
severe obesity (BMI >40) have worse overall survival with no impact on disease free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract